Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot Study
The rationale of the study was to evaluate the efficacy of infliximab (IFX) treatment in patients with ankylosing spondylitis (AS) and to determine whether IFX dose reduction and interval extension sustains the treatment effect. Nineteen patients were included and treated with IFX 5 mg/kg every 6 we...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2013/289845 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841524614462701568 |
|---|---|
| author | Boel Mörck Rille Pullerits Mats Geijer Tomas Bremell Helena Forsblad-d'Elia |
| author_facet | Boel Mörck Rille Pullerits Mats Geijer Tomas Bremell Helena Forsblad-d'Elia |
| author_sort | Boel Mörck |
| collection | DOAJ |
| description | The rationale of the study was to evaluate the efficacy of infliximab (IFX) treatment in patients with ankylosing spondylitis (AS) and to determine whether IFX dose reduction and interval extension sustains the treatment effect. Nineteen patients were included and treated with IFX 5 mg/kg every 6 weeks for 56 weeks. All patients concomitantly received MTX with median dose 7.5 mg/weekly. During the second year, the IFX dose was reduced to 3 mg/kg every 8 weeks. Eighteen patients completed the 1-year and 15 patients the 2-year trial. The ≥50% improvement at week 16 from baseline of BASDAI was achieved in 16/19 (84%) patients. Significant reductions in BASDAI, BASFI, and BASMI scores, decrease in ESR and CRP, and improvement in SF-36 were observed at weeks 16 and 56. The MRI-defined inflammatory changes in the sacroiliac joints disappeared in 10/15 patients (67%) already at 16 weeks. IFX treatment effect was sustained throughout the second year after IFX dose reduction and interval extension. We conclude that IFX treatment is effective in well-established active AS and a dose reduction sustains the treatment effect. These observations are of clinical importance and open the opportunity to reduce the drug costs. This trial is registered with ClinicalTrials.gov NCT01850121. |
| format | Article |
| id | doaj-art-4ba4270ab7e841f7bd2a60ecb8773d1e |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-4ba4270ab7e841f7bd2a60ecb8773d1e2025-02-03T05:47:49ZengWileyMediators of Inflammation0962-93511466-18612013-01-01201310.1155/2013/289845289845Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot StudyBoel Mörck0Rille Pullerits1Mats Geijer2Tomas Bremell3Helena Forsblad-d'Elia4Department of Rheumatology and Inflammation Research, The Sahlgrenska Academy at Gothenburg University, Guldhedsgatan 10A, 41346 Gothenburg, SwedenDepartment of Rheumatology and Inflammation Research, The Sahlgrenska Academy at Gothenburg University, Guldhedsgatan 10A, 41346 Gothenburg, SwedenDepartment of Radiology, Sahlgrenska University Hospital, Bruna stråket 11B, 41345 Gothenburg, SwedenDepartment of Rheumatology and Inflammation Research, The Sahlgrenska Academy at Gothenburg University, Guldhedsgatan 10A, 41346 Gothenburg, SwedenDepartment of Rheumatology and Inflammation Research, The Sahlgrenska Academy at Gothenburg University, Guldhedsgatan 10A, 41346 Gothenburg, SwedenThe rationale of the study was to evaluate the efficacy of infliximab (IFX) treatment in patients with ankylosing spondylitis (AS) and to determine whether IFX dose reduction and interval extension sustains the treatment effect. Nineteen patients were included and treated with IFX 5 mg/kg every 6 weeks for 56 weeks. All patients concomitantly received MTX with median dose 7.5 mg/weekly. During the second year, the IFX dose was reduced to 3 mg/kg every 8 weeks. Eighteen patients completed the 1-year and 15 patients the 2-year trial. The ≥50% improvement at week 16 from baseline of BASDAI was achieved in 16/19 (84%) patients. Significant reductions in BASDAI, BASFI, and BASMI scores, decrease in ESR and CRP, and improvement in SF-36 were observed at weeks 16 and 56. The MRI-defined inflammatory changes in the sacroiliac joints disappeared in 10/15 patients (67%) already at 16 weeks. IFX treatment effect was sustained throughout the second year after IFX dose reduction and interval extension. We conclude that IFX treatment is effective in well-established active AS and a dose reduction sustains the treatment effect. These observations are of clinical importance and open the opportunity to reduce the drug costs. This trial is registered with ClinicalTrials.gov NCT01850121.http://dx.doi.org/10.1155/2013/289845 |
| spellingShingle | Boel Mörck Rille Pullerits Mats Geijer Tomas Bremell Helena Forsblad-d'Elia Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot Study Mediators of Inflammation |
| title | Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot Study |
| title_full | Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot Study |
| title_fullStr | Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot Study |
| title_full_unstemmed | Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot Study |
| title_short | Infliximab Dose Reduction Sustains the Clinical Treatment Effect in Active HLAB27 Positive Ankylosing Spondylitis: A Two-Year Pilot Study |
| title_sort | infliximab dose reduction sustains the clinical treatment effect in active hlab27 positive ankylosing spondylitis a two year pilot study |
| url | http://dx.doi.org/10.1155/2013/289845 |
| work_keys_str_mv | AT boelmorck infliximabdosereductionsustainstheclinicaltreatmenteffectinactivehlab27positiveankylosingspondylitisatwoyearpilotstudy AT rillepullerits infliximabdosereductionsustainstheclinicaltreatmenteffectinactivehlab27positiveankylosingspondylitisatwoyearpilotstudy AT matsgeijer infliximabdosereductionsustainstheclinicaltreatmenteffectinactivehlab27positiveankylosingspondylitisatwoyearpilotstudy AT tomasbremell infliximabdosereductionsustainstheclinicaltreatmenteffectinactivehlab27positiveankylosingspondylitisatwoyearpilotstudy AT helenaforsbladdelia infliximabdosereductionsustainstheclinicaltreatmenteffectinactivehlab27positiveankylosingspondylitisatwoyearpilotstudy |